QIMR Berghofer Medical Research Institute and Bristol-Myers Squibb have signed a research collaboration and licence agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology target.
An opinion piece in the journal Nature, representing over 100 antibody experts around the world, has called for a standardised approach to the creation and use of antibodies in research and therapeutics.
Biotech start-up Solvanix was launched this week with funding from the Medical Research Commercialisation Fund (MRCF). The aim of the company is to commercialise a technology for improving stability and reducing the aggregation (stickiness) of fully human antibodies - a side effect of their purification, concentration and storage for use as therapeutic drugs.
The Enzo Life Sciences Diglycyl Lysine, mAb (GX41), is a highly specific monoclonal for ubiquitin remnant profiling that recognises the diglycyl-lysine residue left behind after the ubiquitin itself is long gone - with no detectable reactivity to non-modified lysines.
Antibody provider Cell Signaling Technology (CST) has entered into a strategic partnership to supply antibodies for use in Dako companion diagnostics products.
Aves Labs chicken-produced neural cell marker antibodies can be used along with existing mouse or rabbit antibodies in double-labelling studies. The neuronal cell markers are made against sequences that are 100% shared between mouse and human proteins, ensuring that the neural cell marker antibodies will react with a wide range of different mammalian species.
The primary cilium acts as a sensory organelle that transfers information from the environment to the cell interior. Proteintech has over 70 antibodies recognising cilia-related proteins.
Rabbit monoclonal (RabMAb) antibodies offer the antigen recognition of the rabbit immune system combined with the specificity and consistency of a monoclonal, providing antibodies with good binding affinity and bioactivity in a wide variety of biological assays.
Enzo Life Sciences CD marker antibodies are available to identify various features and isolate the user's target. Available in either a standard or conjugated format to a variety of detection agents, they can help researchers visualise, identify, purify and target immune cells and tissues that display CD markers on their surfaces.
Improving the product development cycle for new therapies is a constant challenge for drug discovery researchers. With the DiSH kit, Enzo Life Sciences provides a tool to enable rapid detection and production of highly specific monoclonal antibodies.
The IgM antibody PAT-SM6, developed by biotechnology company Patrys, has been produced through a plant-based manufacturing system.
Enzo Life Sciences offers a broad range of native bacterial and viral antigens for the research and in vitro diagnostics markets. Wherever practical, the antigens are isolated and purified from culture. In cases where antigen yield may be very low, the antigens are produced using the latest mammalian expression systems.
vPair antibodies from Abiocode represent a pair of fully characterised antibodies that recognise two different regions of a target protein. The product was developed to address whether the signal observed truly represents the protein of interest, an often encountered issue in antibody-based assays.
The Thunder-Link oligo conjugation system has been designed to allow the non-specialist to generate antibody oligonucelotide conjugates easily and efficiently.
Santa Cruz Biotechnology now offers over 15,661 monoclonal and 41,708 polyclonal antibodies directed to a broad range of mammalian and non-mammalian protein targets.